Replies to post #324663 on Anavex Life Sciences Corp (AVXL)

[BAR123]

Rumors flying on stock twits about a partnership with roche. It might be a bit early for that kind of talk. Maybe towards the end of the year for Alzheimer’s.

[RedShoulder]

Everyone keeps talking about a partnership with a big pharmaceutical.

I'd love to see a partnership with Cassava if their drug works as advertised and can be prescribed alongside A273.

I think the potential for massive profits is significantly higher that way, and Dr. Missling will retain a lot more influence and power over future decision making.

That would be great for SAVA but a bad deal for AVXL since A2-73 prevents the problem SAVA fixes by bring the system into homeostasis upstream at the S1 receptor ahead of SAVA's repairing 'fix'.

A2-73 prevents problems from forming, while SAVA attempts a fix after the problem is prevented by A-273 Blarcamesine in the first place; making SAVA's drug redundant and not needed.

Bringing the system into a healthy homeostasis is the key that A2-73 holds.

That is why investing in SAVA is a bad deal because Anavex will have A2-73 approved and in the market while SAVA is still in trials since Anavex is a year and likely more ahead of SAVA.

SAVA is fishing for a buy out, and that is the reason the SP is doing so well. While Anavex is aiming to be an independent Bio/Pharma.